Kuros Biosciences Ownership
| CSBTF Stock | USD 21.40 3.90 15.42% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Kuros |
Kuros Pink Sheet Ownership Analysis
About 35.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. Kuros Biosciences recorded a loss per share of 0.24. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 23rd of June 2016. Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. KUROS BIOSCIENCES operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 58 people.The quote for Kuros Biosciences AG is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Kuros Biosciences AG please contact BSc BS at 41 44 733 4747 or go to https://www.kuros.ch.Kuros Biosciences Outstanding Bonds
Kuros Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kuros Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kuros bonds can be classified according to their maturity, which is the date when Kuros Biosciences AG has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Currently Active Assets on Macroaxis
Other Information on Investing in Kuros Pink Sheet
Kuros Biosciences financial ratios help investors to determine whether Kuros Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kuros with respect to the benefits of owning Kuros Biosciences security.